<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01255306</url>
  </required_header>
  <id_info>
    <org_study_id>KBSM-30-1/10</org_study_id>
    <nct_id>NCT01255306</nct_id>
  </id_info>
  <brief_title>The Influence of Silicone Oil on Nerve Fiber Layer Thickness After Pars Plana Vitrectomy</brief_title>
  <official_title>The Influence of Silicone Oil on Nerve Fiber Layer Thickness After Pars Plana Vitrectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital &quot;Sestre Milosrdnice&quot;</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital &quot;Sestre Milosrdnice&quot;</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the influence of silicone oil on thickness of the retinal
      nerve fiber layer by using optical coherence tomography (OCT) in patients following pars
      plana vitrectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to evaluate the influence of silicone oil on thickness of the retinal
      nerve fiber layer by using optical coherence tomography (OCT) in patients following pars
      plana vitrectomy.

      The study will include 60 patients with a temporary silicone oil tamponade who will be
      surgically treated with pars plana vitrectomy for rhegmatogenous retinal detachment and
      proliferative vitreoretinopathy. All subjects will be subdued to complete ophthalmologic
      examinations, measurements of the retinal nerve fiber layer thickness by an OCT examination,
      tests of the visual field with the use of an Octopus computed perimeter (automated static
      perimetry) and FDT-perimetry - both prior to the surgery, and on control visits for check-up
      during the postoperative period.

      All results provided by postoperative examinations will be compared with one another.

      The study is expected to provide data on the effect of the silicone oil on thickness of the
      retinal nerve fiber layer. It is also planned to show possibilities and advantages of OCT as
      a method of choice in the follow-up of patients with intraocular silicone oil tamponade.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evidence of Retinal Nerve Fibre Layer Thickness Change Measured by Optical Coherence Tomography</measure>
    <time_frame>6 months</time_frame>
    <description>Retinal nerve fiber layer thickness change measured by optical coherence tomography might be an additional parameter that could provide new insights into clinical decision making in patients with silicone oil tamponade.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retinal Nerve Fiber Layer Thickness Change in Patients With Raised Intraocular Pressure Secondary to Silicone Oil Endotamponade</measure>
    <time_frame>6 months</time_frame>
    <description>To assess whether retinal nerve fiber layer thickness changes in patients with raised intraocular pressure secondary to silicone oil endotamponade.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Rhegmatogenous Retinal Detachment</condition>
  <condition>Toxic Effect of Silicone</condition>
  <condition>Glaucoma Due to Silicon Oil</condition>
  <arm_group>
    <arm_group_label>NO IOP</arm_group_label>
    <description>Patients without raised IOP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RAISED IOP</arm_group_label>
    <description>Patients with raised IOP</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Optical coherence tomography</intervention_name>
    <description>Optical coherence tomography will be performed in all study patients following pars plans vitrectomy and silicone oil tamponade. A fellow eye of each patient will serve as a control. Each patient enrolled in a study will receive 4 measurements:
On 7th postoperative day
On 30th postoperative day
On 90th postoperative day
On 180th postoperative day</description>
    <arm_group_label>NO IOP</arm_group_label>
    <arm_group_label>RAISED IOP</arm_group_label>
    <other_name>Cirrus HD OCT ( Carl Zeiss Meditec, Dublin, CA )</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Local medical treatment of raised intraocular pressure</intervention_name>
    <description>In patients with raised intraocular pressure following medications will be employed in order to control the intraocular pressure:
Cosopt (dorzolamide hydrochloride-timolol maleate ophthalmic solution; b.i.d.) Ganfort (Bimatoprost, timolol maleate ophthalmic solution; once daily) Alphagan (Brimonidine ophthalmic solution; b.i.d.) In patients with intraocular pressure less than 27 mmHg Alphagan will be prescribed. In patients with intraocular pressure greater than 27 mmHg either Cosopt, or Ganfort will be prescribed under the discretion of treating physician. If intraocular pressure in patients treated with either Cosopt or Ganfort does not drop under 21 mmHg, Alphagan will be added.</description>
    <arm_group_label>RAISED IOP</arm_group_label>
    <other_name>1. Cosopt</other_name>
    <other_name>2. Ganfort</other_name>
    <other_name>3. Alphagan</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        tertiary care clinic
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - patients with rhegmatogenous retinal detachment

        Exclusion Criteria:

          -  preexistent glaucoma

          -  previous retinal surgery

          -  placement of scleral buckle during surgery

          -  patients with more than 1/2 of emulsified silicone oil in anterior chamber
             postoperatively

          -  patients who develop silicone oil keratopathy postoperatively

          -  patients who develop silicone oil cataract which blocks visualization of posterior
             segment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mia Zoric Geber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University department of Ophthalmology, University Hospital &quot;Sestre milosrdnice&quot;</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Department of Ophthalmology, University Hospital &quot;Sestre milosrdnice&quot;, Vinogradska 29</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Croatia</country>
  </location_countries>
  <reference>
    <citation>Honavar SG, Goyal M, Majji AB, Sen PK, Naduvilath T, Dandona L. Glaucoma after pars plana vitrectomy and silicone oil injection for complicated retinal detachments. Ophthalmology. 1999 Jan;106(1):169-76; discussion 177.</citation>
    <PMID>9917800</PMID>
  </reference>
  <reference>
    <citation>Al-Jazzaf AM, Netland PA, Charles S. Incidence and management of elevated intraocular pressure after silicone oil injection. J Glaucoma. 2005 Feb;14(1):40-6.</citation>
    <PMID>15650603</PMID>
  </reference>
  <reference>
    <citation>Mastropasqua L, Carpineto P, Ciancaglini M, Falconio G, Harris A. Reproducibility of nerve fiber layer thickness measurements using optical coherence tomography in silicone oil-filled eyes. Ophthalmologica. 2001 Mar-Apr;215(2):91-6.</citation>
    <PMID>11244337</PMID>
  </reference>
  <reference>
    <citation>Leung CK, Cheung CY, Weinreb RN, Qiu Q, Liu S, Li H, Xu G, Fan N, Huang L, Pang CP, Lam DS. Retinal nerve fiber layer imaging with spectral-domain optical coherence tomography: a variability and diagnostic performance study. Ophthalmology. 2009 Jul;116(7):1257-63, 1263.e1-2. doi: 10.1016/j.ophtha.2009.04.013. Epub 2009 May 22.</citation>
    <PMID>19464061</PMID>
  </reference>
  <reference>
    <citation>Kee C, Cho C. Evaluation of retinal nerve fiber layer thickness in the area of apparently normal hemifield in glaucomatous eyes with optical coherence tomography. J Glaucoma. 2003 Jun;12(3):250-4.</citation>
    <PMID>12782844</PMID>
  </reference>
  <reference>
    <citation>Wollstein G, Schuman JS, Price LL, Aydin A, Beaton SA, Stark PC, Fujimoto JG, Ishikawa H. Optical coherence tomography (OCT) macular and peripapillary retinal nerve fiber layer measurements and automated visual fields. Am J Ophthalmol. 2004 Aug;138(2):218-25.</citation>
    <PMID>15289130</PMID>
  </reference>
  <reference>
    <citation>Shah NN, Bowd C, Medeiros FA, Weinreb RN, Sample PA, Hoffmann EM, Zangwill LM. Combining structural and functional testing for detection of glaucoma. Ophthalmology. 2006 Sep;113(9):1593-602.</citation>
    <PMID>16949444</PMID>
  </reference>
  <reference>
    <citation>Yalvac IS, Altunsoy M, Cansever S, Satana B, Eksioglu U, Duman S. The correlation between visual field defects and focal nerve fiber layer thickness measured with optical coherence tomography in the evaluation of glaucoma. J Glaucoma. 2009 Jan;18(1):53-61. doi: 10.1097/IJG.0b013e318179f751.</citation>
    <PMID>19142136</PMID>
  </reference>
  <reference>
    <citation>Inoue M, Iriyama A, Kadonosono K, Tamaki Y, Yanagi Y. Effects of perfluorocarbon liquids and silicone oil on human retinal pigment epithelial cells and retinal ganglion cells. Retina. 2009 May;29(5):677-81. doi: 10.1097/IAE.0b013e318196fca1.</citation>
    <PMID>19174720</PMID>
  </reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2010</study_first_submitted>
  <study_first_submitted_qc>December 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2010</study_first_posted>
  <results_first_submitted>December 18, 2011</results_first_submitted>
  <results_first_submitted_qc>December 18, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 24, 2012</results_first_posted>
  <last_update_submitted>March 22, 2012</last_update_submitted>
  <last_update_submitted_qc>March 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital &quot;Sestre Milosrdnice&quot;</investigator_affiliation>
    <investigator_full_name>Mia Zoric Geber</investigator_full_name>
    <investigator_title>Mia Zoric Geber, MD</investigator_title>
  </responsible_party>
  <keyword>Rhegmatogenous retinal detachment</keyword>
  <keyword>Pars plana vitrectomy</keyword>
  <keyword>Silicone oil</keyword>
  <keyword>Retinal nerve fibre layer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Detachment</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brimonidine Tartrate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients with a diagnosis of retinal detachment who fulfilled enrolment criteria were included in the study. All patient were enrolled through University Department of Ophthalmology, University Hospital &quot;Sestre milosrdnice&quot;.
The recruitment started in April 2010 and the last patient was enrolled in June 2011.</recruitment_details>
      <pre_assignment_details>We excluded one patient who developed severe inflammatory reaction 5 days following pars plana vitrectomy and silicone oile tamponade from the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>NO IOP</title>
          <description>Patients without raised IOP</description>
        </group>
        <group group_id="P2">
          <title>RAISED IOP</title>
          <description>Patients with raised IOP</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NO IOP</title>
          <description>Patients without raised IOP</description>
        </group>
        <group group_id="B2">
          <title>RAISED IOP</title>
          <description>Patients with raised IOP</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="59"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.80" spread="12.97"/>
                    <measurement group_id="B2" value="58.21" spread="12.26"/>
                    <measurement group_id="B3" value="60.67" spread="12.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Croatia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Evidence of Retinal Nerve Fibre Layer Thickness Change Measured by Optical Coherence Tomography</title>
        <description>Retinal nerve fiber layer thickness change measured by optical coherence tomography might be an additional parameter that could provide new insights into clinical decision making in patients with silicone oil tamponade.</description>
        <time_frame>6 months</time_frame>
        <population>We included all patients that have completed necessary follow up visits and have had optical coherence tomography measurements at all visits in the final analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>STUDY EYES</title>
            <description>Study eyes that underwent pars plana vitrectomy and silicone oil tamponade</description>
          </group>
          <group group_id="O2">
            <title>CONTROL EYES</title>
            <description>Fellow eye of each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Evidence of Retinal Nerve Fibre Layer Thickness Change Measured by Optical Coherence Tomography</title>
          <description>Retinal nerve fiber layer thickness change measured by optical coherence tomography might be an additional parameter that could provide new insights into clinical decision making in patients with silicone oil tamponade.</description>
          <population>We included all patients that have completed necessary follow up visits and have had optical coherence tomography measurements at all visits in the final analysis.</population>
          <units>micrometer</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RNFL thickness at 7th postop. day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.23" spread="16.39"/>
                    <measurement group_id="O2" value="87.07" spread="10.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RNFL thickness at 30th postop. day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.09" spread="21.59"/>
                    <measurement group_id="O2" value="87.93" spread="11.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RNFL thickness at 90th postop. day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.56" spread="23.72"/>
                    <measurement group_id="O2" value="87.37" spread="11.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RNFL thickness at 180th postop. day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.40" spread="23.35"/>
                    <measurement group_id="O2" value="88.93" spread="11.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Retinal Nerve Fiber Layer Thickness Change in Patients With Raised Intraocular Pressure Secondary to Silicone Oil Endotamponade</title>
        <description>To assess whether retinal nerve fiber layer thickness changes in patients with raised intraocular pressure secondary to silicone oil endotamponade.</description>
        <time_frame>6 months</time_frame>
        <population>We included all patients who completed follow up visits and who had valid OCT measurements as defined per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>NO IOP</title>
            <description>Patients without raised IOP</description>
          </group>
          <group group_id="O2">
            <title>RAISED IOP</title>
            <description>Patients with raised IOP</description>
          </group>
          <group group_id="O3">
            <title>CONTROL</title>
            <description>Fellow eye of each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Retinal Nerve Fiber Layer Thickness Change in Patients With Raised Intraocular Pressure Secondary to Silicone Oil Endotamponade</title>
          <description>To assess whether retinal nerve fiber layer thickness changes in patients with raised intraocular pressure secondary to silicone oil endotamponade.</description>
          <population>We included all patients who completed follow up visits and who had valid OCT measurements as defined per protocol.</population>
          <units>micrometer</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RNFL thickness at 7th postop. day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.08" spread="15.18"/>
                    <measurement group_id="O2" value="96.34" spread="17.51"/>
                    <measurement group_id="O3" value="87.07" spread="10.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RNFL thickness at 30th postop. day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.76" spread="17.65"/>
                    <measurement group_id="O2" value="97.91" spread="24.35"/>
                    <measurement group_id="O3" value="87.93" spread="11.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RNFL thickness at 90th postop. day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.44" spread="23.08"/>
                    <measurement group_id="O2" value="98.44" spread="24.53"/>
                    <measurement group_id="O3" value="87.37" spread="11.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RNFL thickness at 180th postop. day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.76" spread="23.00"/>
                    <measurement group_id="O2" value="99.34" spread="23.93"/>
                    <measurement group_id="O3" value="88.93" spread="11.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>STUDY EYES</title>
          <description>Study eyes that underwent pars plana vitrectomy and silicone oil tamponade</description>
        </group>
        <group group_id="E2">
          <title>CONTROL EYES</title>
          <description>Fellow eye of each patient</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mia Zoric Geber, MD</name_or_title>
      <organization>University Hospital &quot;Sestre milosrdnice&quot;</organization>
      <phone>+385 1 3787 354</phone>
      <email>mia.zoric-geber@zg.t-com.hr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

